HRP20211015T1 - Cjepivo protiv citomegalovirusa (cmv) - Google Patents
Cjepivo protiv citomegalovirusa (cmv) Download PDFInfo
- Publication number
- HRP20211015T1 HRP20211015T1 HRP20211015TT HRP20211015T HRP20211015T1 HR P20211015 T1 HRP20211015 T1 HR P20211015T1 HR P20211015T T HRP20211015T T HR P20211015TT HR P20211015 T HRP20211015 T HR P20211015T HR P20211015 T1 HRP20211015 T1 HR P20211015T1
- Authority
- HR
- Croatia
- Prior art keywords
- viral vector
- seq
- glycoprotein
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| EP14820762.4A EP3077519B1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211015T1 true HRP20211015T1 (hr) | 2021-10-01 |
Family
ID=52232138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211015TT HRP20211015T1 (hr) | 2013-12-03 | 2014-12-03 | Cjepivo protiv citomegalovirusa (cmv) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (https=) |
| EP (2) | EP3904522A1 (https=) |
| JP (2) | JP6818551B2 (https=) |
| CN (2) | CN115058452A (https=) |
| AU (2) | AU2014359276B2 (https=) |
| CA (1) | CA2932318C (https=) |
| CY (1) | CY1124288T1 (https=) |
| DK (1) | DK3077519T3 (https=) |
| ES (1) | ES2868427T3 (https=) |
| HR (1) | HRP20211015T1 (https=) |
| HU (1) | HUE054579T2 (https=) |
| LT (1) | LT3077519T (https=) |
| PL (1) | PL3077519T3 (https=) |
| PT (1) | PT3077519T (https=) |
| RS (1) | RS61993B1 (https=) |
| SI (1) | SI3077519T1 (https=) |
| WO (1) | WO2015082570A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CN115058452A (zh) * | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| RS63546B1 (sr) * | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| US11572389B2 (en) * | 2017-01-27 | 2023-02-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| JP2020516291A (ja) | 2017-04-14 | 2020-06-11 | レジェンクスバイオ インコーポレーテッド | ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療 |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CN112512569A (zh) | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CA3116175A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| KR102609106B1 (ko) * | 2018-12-10 | 2023-12-05 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신 |
| JP7783631B2 (ja) * | 2019-11-07 | 2025-12-10 | ウニヴェルズィテート バーゼル | ベクターとしてのアレナウイルス |
| KR102837045B1 (ko) | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| BR112023016075A2 (pt) | 2021-02-10 | 2023-11-21 | Regenxbio Inc | Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JP2607712B2 (ja) * | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1265916B1 (en) * | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| SG189176A1 (en) * | 2010-10-15 | 2013-05-31 | Glaxosmithkline Biolog Sa | Cytomegalovirus gb antigen |
| CN103597098A (zh) * | 2011-01-07 | 2014-02-19 | 斯洛伐克生物科学公司 | 病毒诊断 |
| WO2012162428A1 (en) * | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| ES2753138T3 (es) * | 2012-07-06 | 2020-04-07 | Glaxosmithkline Biologicals Sa | Complejos de proteínas de citomegalovirus |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| CN115058452A (zh) | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) * | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| RS63546B1 (sr) | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| US20190135875A1 (en) | 2016-05-18 | 2019-05-09 | Hookipa Biotech Gmbh | Tri-segmented pichinde viruses as vaccine vectors |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| JP7783631B2 (ja) | 2019-11-07 | 2025-12-10 | ウニヴェルズィテート バーゼル | ベクターとしてのアレナウイルス |
| MX2022014725A (es) | 2020-05-29 | 2023-02-09 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. |
-
2014
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160296619A1 (en) | 2016-10-13 |
| AU2014359276B2 (en) | 2021-01-28 |
| SI3077519T1 (sl) | 2021-07-30 |
| JP2017503482A (ja) | 2017-02-02 |
| EP3077519A1 (en) | 2016-10-12 |
| PL3077519T3 (pl) | 2021-10-18 |
| WO2015082570A8 (en) | 2015-11-26 |
| US11554169B2 (en) | 2023-01-17 |
| CN105980570B (zh) | 2022-06-07 |
| CA2932318A1 (en) | 2015-06-11 |
| HK1226440A1 (zh) | 2017-09-29 |
| EP3077519B1 (en) | 2021-03-31 |
| AU2014359276A1 (en) | 2016-06-16 |
| DK3077519T3 (en) | 2021-06-14 |
| RS61993B1 (sr) | 2021-07-30 |
| AU2021202541A1 (en) | 2021-05-27 |
| US20230181725A1 (en) | 2023-06-15 |
| LT3077519T (lt) | 2021-04-26 |
| JP7001807B2 (ja) | 2022-02-04 |
| CA2932318C (en) | 2023-10-10 |
| EP3904522A1 (en) | 2021-11-03 |
| CN115058452A (zh) | 2022-09-16 |
| HUE054579T2 (hu) | 2021-09-28 |
| JP6818551B2 (ja) | 2021-01-20 |
| CN105980570A (zh) | 2016-09-28 |
| US10111945B2 (en) | 2018-10-30 |
| CY1124288T1 (el) | 2022-07-22 |
| US20190247493A1 (en) | 2019-08-15 |
| JP2021061848A (ja) | 2021-04-22 |
| WO2015082570A1 (en) | 2015-06-11 |
| ES2868427T3 (es) | 2021-10-21 |
| PT3077519T (pt) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2017503482A5 (https=) | ||
| JP2021061848A5 (https=) | ||
| Vander Veen et al. | Alphavirus replicon vaccines | |
| Rühl et al. | Vaccination against the Epstein–Barr virus | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2021182922A5 (https=) | ||
| Wang | Nonhuman primate models for Epstein-Barr virus infection | |
| Murrell et al. | Genetic stability of bacterial artificial chromosome-derived human cytomegalovirus during culture in vitro | |
| HRP20201684T1 (hr) | Tri-segmentirani arenavirusi kao vektori cjepiva | |
| Brennan et al. | Mapping of transcription termination within the S segment of SFTS phlebovirus facilitated generation of NSs deletant viruses | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| JP2017510262A5 (https=) | ||
| CN113930452B (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| JP2019511921A5 (https=) | ||
| Shoji et al. | Generation and characterization of P gene-deficient rabies virus | |
| Morimoto et al. | Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity | |
| Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
| Gutiérrez-Álvarez et al. | Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Erdman et al. | Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept | |
| Hidmark et al. | Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling | |
| CN105219740A (zh) | 一种重组人3型腺病毒及制备方法和应用 | |
| CN105274142A (zh) | 复制型重组人55型腺病毒载体及其制备方法和应用 | |
| Truckenmiller et al. | Viral vectors for inducing CD8+ T cell responses |